-
Je něco špatně v tomto záznamu ?
Mutational analysis of driver genes defines the colorectal adenoma: in situ carcinoma transition
J. Jungwirth, M. Urbanova, A. Boot, P. Hosek, P. Bendova, A. Siskova, J. Svec, M. Kment, D. Tumova, S. Summerova, Z. Benes, T. Buchler, P. Kohout, T. Hucl, R. Matej, L. Vodickova, T. van Wezel, P. Vodicka, V. Vymetalkova
Jazyk angličtina Země Velká Británie
Typ dokumentu časopisecké články, práce podpořená grantem
NLK
Directory of Open Access Journals
od 2011
Free Medical Journals
od 2011
Nature Open Access
od 2011-12-01
PubMed Central
od 2011
Europe PubMed Central
od 2011
ProQuest Central
od 2011-01-01
Open Access Digital Library
od 2011-01-01
Open Access Digital Library
od 2011-01-01
Health & Medicine (ProQuest)
od 2011-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2011
Springer Nature OA/Free Journals
od 2011-12-01
- MeSH
- adenom genetika patologie MeSH
- karcinom in situ genetika patologie MeSH
- kolorektální nádory genetika patologie MeSH
- lidé MeSH
- metylace DNA MeSH
- mikrosatelitní nestabilita * MeSH
- mutace * MeSH
- nádorové biomarkery genetika MeSH
- následné studie MeSH
- prognóza MeSH
- senioři MeSH
- Check Tag
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
A large proportion of colorectal carcinomas (CRC) evolve from colorectal adenomas. However, not all individuals with colonic adenomas have a risk of CRC substantially higher than those of the general population. The aim of the study was to determine the differences or similarities of mutation profile among low- and high-grade adenomas and in situ carcinoma with detailed follow up. We have investigated the mutation spectrum of well-known genes involved in CRC (such as APC, BRAF, EGFR, NRAS, KRAS, PIK3CA, POLE, POLD1, SMAD4, PTEN, and TP53) in a large, well-defined series of 96 adenomas and in situ carcinomas using a high-throughput genotyping technique. Besides, the microsatellite instability and APC and MLH1 promoter methylation were studied as well. We observed a high frequency of pathogenic variants in the studied genes. The APC, KRAS and TP53 mutation frequencies were slightly lower in adenoma samples than in in situ carcinoma samples. Further, when we stratified mutation frequency based on the grade, the frequency distribution was as follows: low-grade adenoma-high-grade adenomas-in situ carcinoma: APC gene 42.9-56.0-54.5%; KRAS gene 32.7-32.0-45.5%; TP53 gene 8.2-20.0-18.2%. The occurrence of KRAS mutation was associated with the presence of villous histology and methylation of the APC promoter was significantly associated with the presence of POLE genetic variations. However, no association was noticed with the presence of any singular mutation and occurrence of subsequent adenoma or CRC. Our data supports the multistep model of gradual accumulation of mutations, especially in the driver genes, such as APC, TP53 and KRAS.
Department of Pathology Leiden University Medical Center Leiden The Netherlands
Department of Surgery Weiden Clinic Söllnerstraße 16 92637 Weiden in der Oberpfalz Germany
DT Gastroenterology Roskotova 1 1225 Prague 4 Czech Republic
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22010987
- 003
- CZ-PrNML
- 005
- 20220506131141.0
- 007
- ta
- 008
- 220425s2022 xxk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1038/s41598-022-06498-9 $2 doi
- 035 __
- $a (PubMed)35173208
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xxk
- 100 1_
- $a Jungwirth, Jiri $u Institute of Biology and Medical Genetics, Institute of Physiology, 1st Faculty of Medicine, Charles University, Albertov 4, 128 00, Prague, Czech Republic $u Department of Surgery, Weiden Clinic, Söllnerstraße 16, 92637, Weiden in der Oberpfalz, Germany
- 245 10
- $a Mutational analysis of driver genes defines the colorectal adenoma: in situ carcinoma transition / $c J. Jungwirth, M. Urbanova, A. Boot, P. Hosek, P. Bendova, A. Siskova, J. Svec, M. Kment, D. Tumova, S. Summerova, Z. Benes, T. Buchler, P. Kohout, T. Hucl, R. Matej, L. Vodickova, T. van Wezel, P. Vodicka, V. Vymetalkova
- 520 9_
- $a A large proportion of colorectal carcinomas (CRC) evolve from colorectal adenomas. However, not all individuals with colonic adenomas have a risk of CRC substantially higher than those of the general population. The aim of the study was to determine the differences or similarities of mutation profile among low- and high-grade adenomas and in situ carcinoma with detailed follow up. We have investigated the mutation spectrum of well-known genes involved in CRC (such as APC, BRAF, EGFR, NRAS, KRAS, PIK3CA, POLE, POLD1, SMAD4, PTEN, and TP53) in a large, well-defined series of 96 adenomas and in situ carcinomas using a high-throughput genotyping technique. Besides, the microsatellite instability and APC and MLH1 promoter methylation were studied as well. We observed a high frequency of pathogenic variants in the studied genes. The APC, KRAS and TP53 mutation frequencies were slightly lower in adenoma samples than in in situ carcinoma samples. Further, when we stratified mutation frequency based on the grade, the frequency distribution was as follows: low-grade adenoma-high-grade adenomas-in situ carcinoma: APC gene 42.9-56.0-54.5%; KRAS gene 32.7-32.0-45.5%; TP53 gene 8.2-20.0-18.2%. The occurrence of KRAS mutation was associated with the presence of villous histology and methylation of the APC promoter was significantly associated with the presence of POLE genetic variations. However, no association was noticed with the presence of any singular mutation and occurrence of subsequent adenoma or CRC. Our data supports the multistep model of gradual accumulation of mutations, especially in the driver genes, such as APC, TP53 and KRAS.
- 650 _2
- $a adenom $x genetika $x patologie $7 D000236
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a nádorové biomarkery $x genetika $7 D014408
- 650 _2
- $a karcinom in situ $x genetika $x patologie $7 D002278
- 650 _2
- $a kolorektální nádory $x genetika $x patologie $7 D015179
- 650 _2
- $a metylace DNA $7 D019175
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a následné studie $7 D005500
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 12
- $a mikrosatelitní nestabilita $7 D053842
- 650 12
- $a mutace $7 D009154
- 650 _2
- $a prognóza $7 D011379
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Urbanova, Marketa $u Institute of Biology and Medical Genetics, Institute of Physiology, 1st Faculty of Medicine, Charles University, Albertov 4, 128 00, Prague, Czech Republic $u Department of Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 142 00, Prague, Czech Republic
- 700 1_
- $a Boot, Arnoud $u Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands
- 700 1_
- $a Hosek, Petr $u Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Alej Svobody 76, 323 00, Pilsen, Czech Republic
- 700 1_
- $a Bendova, Petra $u Department of Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 142 00, Prague, Czech Republic $u Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Alej Svobody 76, 323 00, Pilsen, Czech Republic
- 700 1_
- $a Siskova, Anna $u Institute of Biology and Medical Genetics, Institute of Physiology, 1st Faculty of Medicine, Charles University, Albertov 4, 128 00, Prague, Czech Republic $u Department of Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 142 00, Prague, Czech Republic
- 700 1_
- $a Svec, Jiri $u Institute of Molecular Genetics of the Czech Academy of Sciences, Videnska 1083, 142 20, Prague, Czech Republic $u Department of Radiotherapy and Oncology, Third Faculty of Medicine, Charles University, Srobarova 50, 100 34, Prague 10, Czech Republic
- 700 1_
- $a Kment, Milan $u Second Department of Internal Medicine, Third Faculty of Medicine, Charles University, Srobarova 50, 100 34, Prague 10, Czech Republic
- 700 1_
- $a Tumova, Daniela $u DT Gastroenterology, Roskotova 1/1225, Prague 4, Czech Republic
- 700 1_
- $a Summerova, Sandra $u Department of Internal Medicine, Third Faculty of Medicine Charles University and Thomayer University Hospital, Ruska 87, 100 00, Prague, Czech Republic
- 700 1_
- $a Benes, Zdenek $u Department of Internal Medicine, Third Faculty of Medicine Charles University and Thomayer University Hospital, Ruska 87, 100 00, Prague, Czech Republic
- 700 1_
- $a Buchler, Tomas $u Department of Oncology, First Faculty of Medicine, Charles University and Thomayer University Hospital, Videnska 800, 140 59, Prague, Czech Republic
- 700 1_
- $a Kohout, Pavel $u Department of Internal Medicine, Third Faculty of Medicine Charles University and Thomayer University Hospital, Ruska 87, 100 00, Prague, Czech Republic
- 700 1_
- $a Hucl, Tomas $u Department of Hepatogastroenterology, Institute for Clinical and Experimental Medicine, Videnska 1958/9, 140 21, Prague, Czech Republic
- 700 1_
- $a Matej, Radoslav $u Department of Pathology and Molecular Medicine, Third Faculty of Medicine, Charles University and Thomayer University Hospital, Videnska 800, 140 59, Prague, Czech Republic $u Department of Pathology, Third Faculty of Medicine, Charles University and University Hospital Kralovske Vinohrady, Srobarova 50, 100 34, Prague 10, Czech Republic
- 700 1_
- $a Vodickova, Ludmila $u Institute of Biology and Medical Genetics, Institute of Physiology, 1st Faculty of Medicine, Charles University, Albertov 4, 128 00, Prague, Czech Republic $u Department of Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 142 00, Prague, Czech Republic $u Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Alej Svobody 76, 323 00, Pilsen, Czech Republic
- 700 1_
- $a van Wezel, Tom $u Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands
- 700 1_
- $a Vodicka, Pavel $u Institute of Biology and Medical Genetics, Institute of Physiology, 1st Faculty of Medicine, Charles University, Albertov 4, 128 00, Prague, Czech Republic $u Department of Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 142 00, Prague, Czech Republic $u Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Alej Svobody 76, 323 00, Pilsen, Czech Republic
- 700 1_
- $a Vymetalkova, Veronika $u Institute of Biology and Medical Genetics, Institute of Physiology, 1st Faculty of Medicine, Charles University, Albertov 4, 128 00, Prague, Czech Republic. veronika.vymetalkova@iem.cas.cz $u Department of Molecular Biology of Cancer, Institute of Experimental Medicine of the Czech Academy of Sciences, Videnska 1083, 142 00, Prague, Czech Republic. veronika.vymetalkova@iem.cas.cz $u Biomedical Center, Faculty of Medicine in Pilsen, Charles University, Alej Svobody 76, 323 00, Pilsen, Czech Republic. veronika.vymetalkova@iem.cas.cz
- 773 0_
- $w MED00182195 $t Scientific reports $x 2045-2322 $g Roč. 12, č. 1 (2022), s. 2570
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/35173208 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y p $z 0
- 990 __
- $a 20220425 $b ABA008
- 991 __
- $a 20220506131133 $b ABA008
- 999 __
- $a ok $b bmc $g 1788881 $s 1162185
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2022 $b 12 $c 1 $d 2570 $e 20220216 $i 2045-2322 $m Scientific reports $n Sci Rep $x MED00182195
- LZP __
- $a Pubmed-20220425
